A new drug currently known as NG101 reduced nausea and vomiting in patients with obesity using GLP-1s by 40% and 67%, respectively

Duvakitug, a novel anti-TL1a monoclonal antibody, demonstrated statistically significant differences in endoscopic response rates compared to placebo in adults

In this issue of Perspectives, we present two timely essays that explore how AI is reshaping clinical care—while also emphasizing the need for caution, thoughtf

fewer than half of adults who started colorectal cancer (CRC) screening with an at-home stool test completed the recommended repeat test, creating gaps in prote

Prior exposure to tumor necrosis factor (TNF) antagonists may weaken the benefit of some advanced therapies for ulcerative colitis (UC) while enhancing the effi

Routine use of artificial intelligence (AI) may lead to a loss of skills among clinicians who perform colonoscopies, thereby affecting patient outcomes

The FDA has granted accelerated approval to Novo Nordisk’s Wegovy for the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate-to-ad

People receiving blood-based colorectal screening tests showed disappointingly low rates of receiving follow-up colonoscopies that are essential when tests are

Medications for inflammatory bowel disease (IBD) appear to have no impact on risk of incident malignancies among patients with a history of breast cancer

Early-onset gastrointestinal (GI) cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced prevention strategi

Emerging research indicates that phenotype-based testing may help identify which biologic process is driving an individual’s obesity

This study shows that tofacitinib is safe and doesn’t impair wound healing or lead to more infections if the patient needs an urgent colectomy

New and Emerging Treatments for MASLD/MASH